12:00 AM
 | 
Nov 05, 2012
 |  BC Week In Review  |  Company News  |  Deals

Oxford BioTherapeutics, Menarini deal

Oxford partnered with Menarini to develop five of Oxford's antibody and antibody-drug conjugate (ADC) programs for undisclosed cancer indications. Oxford will provide undisclosed targets, antibodies and "arming technologies." Menarini will be responsible for...

Read the full 141 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >